VIVI — TempraMed Technologies Income Statement
0.000.00%
Last trade - 00:00- CA$54.87m
- CA$55.65m
- $1.84m
Annual income statement for TempraMed Technologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 1.8 | 1.68 | 2.26 | 1.84 |
| Cost of Revenue | ||||
| Gross Profit | 1.19 | 1.2 | 1.42 | 0.896 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 3.04 | 4.88 | 4.53 | 19.7 |
| Operating Profit | -1.25 | -3.2 | -2.27 | -17.9 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -1.24 | -3.25 | -3.35 | -18.2 |
| Net Income After Taxes | -1.24 | -3.25 | -3.35 | -18.2 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -1.24 | -3.25 | -3.35 | -18.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -1.24 | -3.25 | -3.35 | -18.2 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.016 | -0.042 | -0.043 | -0.062 |